HC Wainwright Analysts Boost Earnings Estimates for ADCT

ADC Therapeutics SA (NYSE:ADCT) – Stock analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of ADC Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.39) per share for the quarter, up from their previous estimate of ($0.41). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

ADC Therapeutics (NYSE:ADCT) last posted its earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $19.00 million for the quarter, compared to analyst estimates of $19.01 million.

Several other research firms have also weighed in on ADCT. Cantor Fitzgerald reiterated an “overweight” rating on shares of ADC Therapeutics in a report on Friday, March 7th. Guggenheim dropped their price objective on ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Stephens boosted their target price on ADC Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, ADC Therapeutics currently has a consensus rating of “Buy” and an average target price of $7.75.

ADC Therapeutics Price Performance

ADC Therapeutics stock opened at $1.36 on Thursday. The firm has a market capitalization of $131.01 million, a price-to-earnings ratio of -0.57 and a beta of 1.51. The company’s 50 day simple moving average is $1.64 and its 200 day simple moving average is $2.22. ADC Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $5.38.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ADCT. Kazazian Asset Management LLC acquired a new position in shares of ADC Therapeutics during the 4th quarter worth $26,000. Two Sigma Securities LLC bought a new stake in ADC Therapeutics in the fourth quarter worth approximately $30,000. Russell Investments Group Ltd. boosted its stake in ADC Therapeutics by 122.6% during the fourth quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company’s stock worth $33,000 after acquiring an additional 9,248 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of ADC Therapeutics during the fourth quarter valued at approximately $35,000. Finally, Intech Investment Management LLC acquired a new position in ADC Therapeutics during the third quarter worth $41,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.